These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38530948)

  • 1. Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
    Giorgino F; Franco DR; Nicolay C; Hemmingway A; Rodríguez Á; Wiese RJ
    Diabetes Care; 2024 Jun; 47(6):1020-1027. PubMed ID: 38530948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
    Zeitler P; Galindo RJ; Davies MJ; Bergman BK; Thieu VT; Nicolay C; Allen S; Heine RJ; Lee CJ
    Diabetes Care; 2024 Jun; 47(6):1056-1064. PubMed ID: 38639997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
    Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
    Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
    Frias JP; De Block C; Brown K; Wang H; Thomas MK; Zeytinoglu M; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1745-1753. PubMed ID: 38252888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
    Rosenstock J; Frías JP; Rodbard HW; Tofé S; Sears E; Huh R; Fernández Landó L; Patel H
    JAMA; 2023 Nov; 330(17):1631-1640. PubMed ID: 37786396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
    Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
    Bao Y; Han L; Du L; Ji L
    Obesity (Silver Spring); 2024 Jun; 32(6):1102-1113. PubMed ID: 38803303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
    Nicholls SJ; Tofé S; le Roux CW; D'Alessio DA; Wiese RJ; Pavo I; Brown K; Weerakkody GJ; Zeytinoglu M; Romera IC
    Cardiovasc Diabetol; 2024 Feb; 23(1):63. PubMed ID: 38341541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Ma J; Liu M; Wang R; Du L; Ji L
    Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
    Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
    Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
    Pedersen SD; Giorgino F; Umpierrez G; Thieu VT; Rodríguez A; Nicolay C; Fernández Landó L; Karanikas CA; Kiljanski J
    Diabetes Obes Metab; 2023 Sep; 25(9):2553-2560. PubMed ID: 37246796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
    Ghosal S; Sinha B; Gangopadhyay KK
    Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.